Ernexa Therapeutics Inc. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31)
Ernexa Therapeutics Inc. (ERNA) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31) of -$20.00 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2013-03-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax · last filed 2013-03-29
- Ernexa Therapeutics Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2013-01-31) for fiscal 2011 was -$20.00K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|
| 2011-12-31 | -$20.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |